Patents Assigned to TeneoBio, Inc.
-
Publication number: 20260159566Abstract: Provided are chimeric antigen receptors (CARs) having antigen specificity for B-cell Maturation Antigen (BCMA). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.Type: ApplicationFiled: February 5, 2026Publication date: June 11, 2026Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, TeneoBio, Inc.Inventors: James N. Kochenderfer, Norris Lam, Nathan Trinklein, Katherine E. Harris, Shelley Force Aldred, Wim Van Schooten
-
Patent number: 12590163Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.Type: GrantFiled: August 29, 2023Date of Patent: March 31, 2026Assignee: TENEOBIO, INC.Inventors: Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
-
Patent number: 12570717Abstract: Provided are chimeric antigen receptors (CARs) having antigen specificity for B-cell Maturation Antigen (BCMA). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.Type: GrantFiled: November 30, 2023Date of Patent: March 10, 2026Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, TeneoBio, Inc.Inventors: James N. Kochenderfer, Norris Lam, Nathan Trinklein, Katherine E. Harris, Shelley Force Aldred, Wim Van Schooten
-
Patent number: 12495776Abstract: Human or chimeric heavy chain-only antibodies are provided, in the native amino acid residue at the first position of the fourth framework region (FR4) of said HCAb is substituted by a different amino acid residue that is capable of disrupting a surface-exposed hydrophobic patch comprising or associated with the native amino acid residue at that position.Type: GrantFiled: August 22, 2017Date of Patent: December 16, 2025Assignee: TeneoBio, Inc.Inventors: Wim van Schooten, Nathan Trinklein, Shelley Force Aldred, Marianne Bruggemann, Mike Osborn
-
Patent number: 12371505Abstract: Anti-BCMA heavy chain-only antibodies(HCAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.Type: GrantFiled: June 29, 2022Date of Patent: July 29, 2025Assignee: TeneoBio, Inc.Inventors: Shelley Force Aldred, Nathan Trinklein, Katherine E. Harris, Kevin Dang, Wim van Schooten
-
Publication number: 20250236681Abstract: Anti-PSMA heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of PSMA.Type: ApplicationFiled: November 19, 2024Publication date: July 24, 2025Applicant: TENEOBIO, INC.Inventors: Wim VAN SCHOOTEN, Starlynn CLARKE, Kevin DANG, Ben BUELOW
-
Patent number: 12180298Abstract: Anti-PSMA heavy chain antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of PSMA.Type: GrantFiled: April 3, 2020Date of Patent: December 31, 2024Assignee: TENEOBIO, INC.Inventors: Wim van Schooten, Starlynn Clarke, Kevin Dang, Ben Buelow
-
Patent number: 11970540Abstract: Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.Type: GrantFiled: June 20, 2018Date of Patent: April 30, 2024Assignee: TENEOBIO, INC.Inventors: Nathan Trinklein, Shelley Force Aldred, Katherine Harris, Wim van Schooten
-
Publication number: 20240091264Abstract: Provided are chimeric antigen receptors (CARs) having antigen specificity for B-cell Maturation Antigen (BCMA). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.Type: ApplicationFiled: November 30, 2023Publication date: March 21, 2024Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, TeneoBio, Inc.Inventors: James N. Kochenderfer, Norris Lam, Nathan Trinklein, Katherine E. Harris, Shelley Force Aldred, Wim Van Schooten
-
Patent number: 11905326Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) binding to CD22 and CD3 are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of CD22.Type: GrantFiled: June 12, 2020Date of Patent: February 20, 2024Assignee: TeneoBio, Inc.Inventors: Nathan Trinklein, Udaya Rangaswamy, Suhasini Iyer, Kirthana Prabhakar, Harshad Ugamraj
-
Patent number: 11884735Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.Type: GrantFiled: February 3, 2023Date of Patent: January 30, 2024Assignee: TENEOBIO, INC.Inventors: Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
-
Patent number: 11873336Abstract: Anti-CD22 heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B cell disorders that are characterized by the expression of CD22.Type: GrantFiled: December 21, 2018Date of Patent: January 16, 2024Assignee: TENEOBIO, INC.Inventors: Shelley Force Aldred, Wim van Schooten, Heather Anne N. Ogana, Laura Marie Davison, Katherine Harris, Udaya Rangaswamy, Nathan D. Trinklein
-
Patent number: 11613572Abstract: The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.Type: GrantFiled: June 20, 2017Date of Patent: March 28, 2023Assignee: TeneoBio, Inc.Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
-
Patent number: 11505606Abstract: The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.Type: GrantFiled: June 20, 2017Date of Patent: November 22, 2022Assignee: TeneoBio, Inc.Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
-
Patent number: 11434299Abstract: Anti-BCMA heavy chain-only antibodies (HCAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.Type: GrantFiled: December 21, 2017Date of Patent: September 6, 2022Assignee: TeneoBio, Inc.Inventors: Shelley Force Aldred, Nathan Trinklein, Katherine E. Harris, Kevin Dang, Wim van Schooten
-
Publication number: 20200138865Abstract: Provided are chimeric antigen receptors (CARs) having antigen specificity for B-cell Maturation Antigen (BCMA). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.Type: ApplicationFiled: June 28, 2018Publication date: May 7, 2020Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, TeneoBio, Inc.Inventors: James N. Kochenderfer, Norris Lam, Nathan Trinklein, Katherine E. Harris, Shelley Force Aldred, Wim Van Schooten
